Hims & Hers misses revenue estimates as strategy shift hits sales - Reuters
Hims & Hers misses revenue estimates as strategy shift hits sales Reuters
Coverage by Political Leaning
See how different sides of the spectrum reported this story
Notable Quotes
"We historically had focused on operating cash flow, which remained positive. It’s the North Star for the company."
— Yemi Okupe , Executive
"We may not be the first to sell peptides, but we would do so 'at scale.'"
— Andrew Dudum , Executive
"2026 is a defining year for Hims & Hers. We’re not just growing, we’re pulling away from the field on our path to becoming the world’s largest consumer health platform."
— Andrew Dudum , Executive
"In the first quarter, we made a strategic pivot that expanded our assortment of branded GLP-1 products, and early demand signals show our consumer reach broadening meaningfully."
— Yemi Okupe , Executive
Key People
CEO of Hims & Hers Health.
Hims & Hers Health is a publicly traded healthcare company focused on telehealth and wellness products.
Analyst at Truist.
Analyst at Morningstar.
Chief Financial Officer of Hims & Hers Health.
Tags
All Coverage
<a href="https://news.google.com/rss/articles/CBMilgFBVV95cUxQanhQZGhFWml1WURBSEhTdnJYU0RKR2lLdDdCV3phSDc5Q2VGa2RMRFRvU1BNRkVrQ3RrV3Q3T000aG9kdlg2NS1QU0xiMGpwZHlNUUdlSXZBQ3dvOE12Y0R0eXlabFpFUG9iTk8wdHIzQlJpZVQ2VEgzd3B4eWNfM1RBT200LVlUUnJFVks2SFpJU0FmSXc?oc=5" target="_blank">Hims & Hers misses revenue estimates as strategy shift hits sales</a> <font color="#6f6f6f">Reuters</font>
Hims & Hers reported a net loss of $92.1 million in Q1 2026, primarily due to a shift in revenue recognition for certain weight-loss offerings, including the Hers brand, resulting from a change to shorter shipping cadences.
Hims & Hers reported Q1 2026 revenue of $608 million, a 4% year-over-year increase, and raised its full-year 2026 revenue guidance to a range of $2.8 billion to $3.0 billion, up from the previous forecast of $2.7 billion to $2.9 billion.
Hims & Hers Health, Inc. reported its first-quarter 2026 financial results, including revenue of approximately $608 million, a 4% year-over-year increase, and raised its full-year 2026 revenue guidance to a range of $2.8 billion to $3.0 billion.
Hims & Hers has undergone a significant business model shift, moving from a high-margin manufacturer to a lower-margin distributor, following regulatory challenges and a patent infringement lawsuit from Novo Nordisk.
Hims & Hers Health raised its 2026 revenue forecast, betting on increased sales for its personalized healthcare offerings. The company now expects annual revenue between $2.8 billion and $3 billion, compared to its previous forecast of $2.7 billion to $2.9 billion.
Similar Stories
Related coverage based on topic and tags
Levi Strauss lifts annual profit outlook on tariff refunds, holiday demand - Reuters
Levi Strauss lifts annual profit outlook on tariff refunds, holiday demand Reuters
October 7, 2026 at 10:10 PMApplied Digital's revenue soars, loss widens on growing AI investments - Reuters
Applied Digital's revenue soars, loss widens on growing AI investments Reuters
October 7, 2026 at 09:23 PMMattel investor Ariel pushes for sale as turnaround stalls - Reuters
Mattel investor Ariel pushes for sale as turnaround stalls Reuters
October 5, 2026 at 10:46 PMAmazon makes fresh job cuts, mainly in retail division - Reuters
Amazon makes fresh job cuts, mainly in retail division Reuters
October 8, 2026 at 01:16 AMPorsche braces for lower sales era, seeks lifeline from luxury - Reuters
Porsche braces for lower sales era, seeks lifeline from luxury Reuters
October 7, 2026 at 06:02 AMPepsiCo to cut costs as weak N.America business hurts core profit forecast - Reuters
PepsiCo to cut costs as weak N.America business hurts core profit forecast Reuters
October 8, 2026 at 11:26 AM